Exosomes versus stem cells: what joint regeneration gains in 2026
Original title: Exosomas vs células madre para regeneración articular: ¿qué dice la evidencia en 2026?
A comprehensive review of exosome therapies for osteoarthritis marks a clinical inflection point: these extracellular vesicles demonstrate superior safety profiles compared to mesenchymal stem cell injections while maintaining comparable efficacy at twelve months according to available phase 2 trials. This finding reframes the risk-benefit equation guiding regenerative medicine decisions in joint care, where differential tolerability becomes clinically material for populations with multiple comorbidities. For those pursuing premium joint regeneration and cartilage preservation protocols, the 2026 evidence suggests exosomes represent a lower immunological burden alternative without compromising regenerative performance over the medium term.
Editorial summary by LongevityMap. For the full article and references, visit Longevity Technology.